8-K: Apogee Reports Q3 2025, APG333 Phase 1 Success

Apogee Therapeutics announced its Q3 2025 financial results and positive interim Phase 1 data for APG333, supporting potential 3to 6-month dosing.

Summary

• Apogee Therapeutics reported a net loss of $65.0 million for the quarter ended September 30, 2025, compared to a net loss of $49.0 million for the same period in 2024.
• Research and development (R&D) expenses increased to $54.2 million in Q3 2025 from $45.7 million in Q3 2024, driven by pipeline advancement and team growth.
• General and administrative (G&A) expenses rose to $17.1 million in Q3 2025 from $13.0 million in Q3 2024, due to increased headcount and equity-based compensation.
• Cash, cash equivalents, and marketable securities were $588.9 million as of September 30, 2025.
• Following a $345 million public offering completed in October, the pro forma cash position as of September 30, 2025, is $913 million, extending the cash runway into the second half of 2028.
• Interim Phase 1 results for APG333 in healthy volunteers exceeded trial objectives, demonstrating a half-life of approximately 55 days and suppressing key biomarkers for 6 months after a single dose.
• APG333 was well tolerated across all cohorts, with doses up to 1,000 mg, and no Grade 3 treatment-emergent adverse events (TEAEs) related to the study drug or serious adverse events were reported.
• APG777 trial readout timelines have been accelerated, with Phase 1b data in asthma and APEX 52-week Part A data in AD anticipated in Q1 2026, and APEX 16-week Part B data in AD in Q2 2026.
• The Phase 1b head-to-head readout of APG279 (APG777+APG990) against DUPIXENT in Atopic Dermatitis (AD) is expected in the second half of 2026.

Sentiment

Score: 8

Explanation: The filing presents strong positive clinical data for APG333, accelerated timelines for APG777, and a significant capital raise that extends the financial runway, all of which are highly favorable for a clinical-stage biotech company despite increased operating losses.

Positives

• Positive interim Phase 1 results for APG333 demonstrated an optimized pharmacokinetic (PK) profile with a half-life of approximately 55 days, supporting potential 3and 6-month dosing.
• APG333 showed depth of suppression in key biomarkers (eosinophils and IL-5) consistent with TSLP analogs and durability out to 6 months.
• APG333 was well tolerated across all tested doses up to 1,000 mg, with generally mild and self-limited treatment-emergent adverse events (TEAEs) and no dose-dependent trends.
• The successful completion of a $345 million public equity offering significantly strengthened the cash position to $913 million pro forma, extending the cash runway into the second half of 2028 and through APG777 Phase 3 topline data.
• Accelerated readout guidance for APG777, with Phase 1b data in asthma and APEX 52-week Part A data in AD now anticipated in Q1 2026, and APEX 16-week Part B data in Q2 2026.
• The results for APG333 support the development of a quarterly or less frequently dosed co-formulation of APG273 (APG777+APG333) for respiratory indications.
• APG777 previously met its primary endpoint in APEX Part A, demonstrating a 71.0% EASI reduction from baseline compared to 33.8% for placebo (p < 0.001).

Negatives

• Net loss increased to $65.0 million for Q3 2025, up from $49.0 million in Q3 2024.
• Research and development expenses increased by $8.5 million to $54.2 million in Q3 2025 compared to Q3 2024.
• General and administrative expenses increased by $4.1 million to $17.1 million in Q3 2025 compared to Q3 2024.

Risks

• Global macroeconomic conditions and related volatility.
• Expectations regarding the initiation, progress, and expected results of preclinical studies, clinical trials, and research and development programs.
• The unpredictable relationship between preclinical study results and clinical study results.
• The timing or likelihood of regulatory filings and approvals.
• Liquidity and capital resources.
• Other risks and uncertainties identified in previous SEC filings, including the Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q.

Future Outlook

Apogee Therapeutics anticipates a potentially transformative 2026 with four key clinical data readouts, including APG777 Phase 1b in asthma and APEX Part A/B data in AD, and APG279 head-to-head data against DUPIXENT. The company plans to initiate Phase 3 trials for APG777 in AD in the second half of 2026, pending results from Part A and Part B. The current cash resources are expected to fund operations into the second half of 2028, covering APG777 Phase 3 topline data.

Management Comments

• "Apogee is gearing up for a potentially transformative 2026 from a position of strength. With four key readouts coming in 2026 and the recent financing providing us runway through Phase 3 topline data for our lead program, APG777 in atopic dermatitis, we believe we are well positioned to advance our therapies to patients as quickly as possible." Michael Henderson, M.D., Chief Executive Officer.
• "In conjunction with our third quarter results, we are pleased to share first-in-human data for APG333, which, together with APG777, we believe could prove to be a best-in-class combination approach for respiratory indications, with the potential for dosing every three months or even less frequently." Michael Henderson, M.D., Chief Executive Officer.
• "Today's positive results show that our engineered antibody approach continues to deliver durable activity, which may enable less frequent dosing versus currently available agents, potentially improving adherence and outcomes for patients. This milestone represents another important step forward for our pipeline in the evolution of I&I treatments." Michael Henderson, M.D., Chief Executive Officer.
• "The extended PK and favorable tolerability profile of APG333 underscores Apogee's potential to advance a quarterly or better dosing combination of APG777 and APG333, designed to address key drivers of respiratory diseases more broadly than a monotherapy." Michael Henderson, M.D., Chief Executive Officer.
• "We are encouraged by these initial results, which further highlight the potential of TSLP inhibition, a clinically validated target that plays an important role in promoting immune cell recruitment and activation." Carl Dambkowski, M.D., Chief Medical Officer.
• "APG333's PK profile supports the potential for dosing two to four times a year, a significant advancement over the current standard of care. These data unlock our combination of APG777 and APG333, which together demonstrated suppression of complementary pathways implicated in obstructive airway disease and may enable quarterly or less frequent dosing, expanding options for patients with limited available treatments." Carl Dambkowski, M.D., Chief Medical Officer.

Industry Context

Apogee Therapeutics operates in the large and growing inflammatory and immunology (I&I) markets, focusing on conditions like Atopic Dermatitis (AD) and asthma. The company's strategy involves developing optimized, novel biologics that target clinically validated mechanisms (IL-13, TSLP, OX40L) with extended half-lives. This approach aims to offer best-in-class efficacy and less frequent dosing compared to existing therapies, such as DUPIXENT. The development of combination therapies like APG279 (APG777+APG990) and APG273 (APG777+APG333) is designed to address disease drivers more broadly and potentially improve patient outcomes and adherence.

Comparison to Industry Standards

• APG777 aims to demonstrate maintenance of EASI-75 and/or IGA 0,1 responses at levels similar or better than DUPIXENT, but with quarterly or better dosing.
• APG333's half-life of approximately 55 days supports potential 3and 6-month dosing, which is presented as a significant advancement over the current standard of care for TSLP inhibition, where one approved product exists for severe asthma.
• Key biomarkers of eosinophils and IL-5 showed depth of suppression in line with TSLP analogs, indicating competitive pharmacological activity.
• APG279 (APG777+APG990) is being evaluated in a head-to-head trial against DUPIXENT in AD, aiming for improved clinical responses over monotherapy.

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical data, extended cash runway, and accelerated pipeline progress, potentially de-risking future development and increasing long-term value.
• Patients: Potential for novel, best-in-class therapies with less frequent dosing for inflammatory and immunology conditions like AD and asthma, offering improved adherence and outcomes.
• Employees: Continued growth and expansion of operations, including the R&D team, supporting increased headcount and equity-based compensation.
• Creditors: Improved financial stability and extended runway reduce immediate liquidity concerns.

Next Steps

• Anticipated readout for APG777 Phase 1b data in patients with mild-to-moderate asthma in Q1 2026.
• Anticipated readout for APEX 52-week Part A data (maintenance phase) in AD in Q1 2026.
• Anticipated readout for APEX 16-week Part B data (optimized dose) in AD in Q2 2026.
• Anticipated interim readout from the APG279 Phase 1b head-to-head trial against DUPIXENT in AD in 2H 2026.
• Planned initiation of Phase 3 trials for APG777 in AD in 2H 2026, pending results from Part A and Part B of the APEX trial.
• Continued development of a quarterly or less frequently dosed co-formulation of APG273 (APG777+APG333) for respiratory indications.

Key Dates

Recommendation

The positive interim Phase 1 results for APG333, demonstrating a long half-life and durable biomarker suppression, coupled with accelerated timelines for the lead program APG777, significantly de-risk the pipeline. The successful $345 million capital raise provides a robust cash runway into 2H 2028, funding operations through critical Phase 3 data for APG777. These developments position Apogee for substantial value creation, making it a strong buy for investors seeking exposure to innovative I&I biologics. While operating losses increased, this is expected for a clinical-stage biotech advancing multiple programs.

Keywords

Apogee Therapeutics, APGE, biotechnology, clinical-stage, inflammatory, immunology, I&I, atopic dermatitis, AD, asthma, TSLP, IL-13, OX40L, APG777, APG333, APG279, APG273, Phase 1, Phase 1b, Phase 2, clinical trial, financial results, Q3 2025, public offering, cash runway, biologics, monoclonal antibody, DUPIXENT